LCTX
Income statement / Annual
Last year (2024), Lineage Cell Therapeutics, Inc.'s total revenue was $9.50 M,
an increase of 6.19% from the previous year.
In 2024, Lineage Cell Therapeutics, Inc.'s net income was -$18.61 M.
See Lineage Cell Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$9.50 M |
$8.95 M |
$14.70 M |
$3.90 M |
$773,000.00 |
$1.48 M |
$1.42 M |
$1.79 M |
$2.25 M |
$2.53 M |
| Cost of Revenue |
$334,000.00
|
$671,000.00
|
$728,000.00
|
$1.43 M
|
$385,000.00
|
$412,000.00
|
$302,000.00
|
$168,000.00
|
$358,000.00
|
$1.11 M
|
| Gross Profit |
$9.17 M
|
$8.27 M
|
$13.98 M
|
$2.47 M
|
$388,000.00
|
$1.07 M
|
$1.11 M
|
$1.62 M
|
$1.89 M
|
$1.43 M
|
| Gross Profit Ratio |
0.96
|
0.92
|
0.95
|
0.63
|
0.5
|
0.72
|
0.79
|
0.91
|
0.84
|
0.56
|
| Research and Development Expenses |
$12.47 M
|
$15.71 M
|
$13.99 M
|
$33.91 M
|
$12.32 M
|
$17.95 M
|
$20.96 M
|
$24.02 M
|
$36.11 M
|
$42.60 M
|
| General & Administrative Expenses |
$18.17 M
|
$17.30 M
|
$22.51 M
|
$18.21 M
|
$15.57 M
|
$24.03 M
|
$24.73 M
|
$19.92 M
|
$28.43 M
|
$29.13 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.17 M
|
$17.30 M
|
$22.51 M
|
$18.21 M
|
$15.57 M
|
$24.03 M
|
$24.73 M
|
$19.92 M
|
$28.43 M
|
$29.13 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$2.15 M
|
-$445,000.00
|
-$1.05 M
|
-$2.04 M
|
-$1.32 M
|
$1.45 M
|
-$403,000.00
|
-$160,000.00
|
| Operating Expenses |
$30.64 M
|
$33.01 M
|
$36.50 M
|
$51.68 M
|
$26.84 M
|
$39.94 M
|
$42.11 M
|
$42.28 M
|
$60.86 M
|
$67.24 M
|
| Cost And Expenses |
$30.98 M
|
$33.68 M
|
$37.22 M
|
$53.11 M
|
$27.22 M
|
$40.35 M
|
$42.41 M
|
$42.45 M
|
$61.22 M
|
$68.34 M
|
| Interest Income |
$1.72 M
|
$1.63 M
|
$829,000.00
|
$2,000.00
|
$1.04 M
|
$1.69 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$5.18 M
|
$0.00
|
$0.00
|
$1.69 M
|
$10.87 M
|
$692,000.00
|
$747,000.00
|
$340,000.00
|
| Depreciation & Amortization |
$0.00
|
$692,000.00
|
$727,000.00
|
$887,000.00
|
$2.11 M
|
$3.13 M
|
$3.27 M
|
$3.30 M
|
$4.76 M
|
$6.33 M
|
| EBITDA |
-$21.48 M |
-$24.04 M |
-$21.79 M |
-$48.34 M |
-$24.41 M |
-$38.88 M |
-$37.72 M |
-$37.36 M |
-$54.21 M |
-$59.48 M |
| EBITDA Ratio |
-2.26
|
-2.69
|
-1.35
|
-13.55
|
-32.36
|
-36.74
|
-22.73
|
-30.12
|
-63.22
|
-24.93
|
| Operating Income Ratio |
-2.26
|
-2.77
|
-1.53
|
-12.63
|
-34.21
|
-26.3
|
-29.52
|
-21.71
|
-26.18
|
-25.97
|
| Total Other Income/Expenses Net |
$2.90 M
|
$1.45 M
|
-$3.29 M
|
$5.94 M
|
$4.52 M
|
$19.64 M
|
-$5.34 M
|
$15.61 M
|
$77.59 M
|
$3.16 M
|
| Income Before Tax |
-$18.58 M
|
-$23.28 M
|
-$25.81 M
|
-$43.27 M
|
-$21.92 M
|
-$19.23 M
|
-$47.13 M
|
-$23.29 M
|
$18.62 M
|
-$62.65 M
|
| Income Before Tax Ratio |
-1.96
|
-2.6
|
-1.76
|
-11.11
|
-28.36
|
-13.01
|
-33.28
|
-13
|
8.27
|
-24.72
|
| Income Tax Expense |
$27,000.00
|
-$1.80 M
|
$541,000.00
|
-$4.71 M
|
-$1.24 M
|
-$7.41 M
|
-$346,000.00
|
-$37.29 M
|
-$175.95 M
|
-$4.52 M
|
| Net Income |
-$18.61 M
|
-$21.49 M
|
-$26.35 M
|
-$38.56 M
|
-$20.69 M
|
-$11.83 M
|
-$45.99 M
|
-$19.98 M
|
$33.57 M
|
-$46.99 M
|
| Net Income Ratio |
-1.96
|
-2.4
|
-1.79
|
-9.9
|
-26.76
|
-8
|
-32.48
|
-11.15
|
14.91
|
-18.54
|
| EPS |
-0.093 |
-0.12 |
-0.16 |
-0.23 |
-0.14 |
-0.0813 |
-0.36 |
-0.17 |
0.35 |
-0.59 |
| EPS Diluted |
-0.093 |
-0.12 |
-0.16 |
-0.23 |
-0.14 |
-0.0813 |
-0.36 |
-0.17 |
0.34 |
-0.59 |
| Weighted Average Shares Out |
$200.19 M
|
$172.66 M
|
$169.79 M
|
$164.50 M
|
$150.04 M
|
$145.53 M
|
$126.90 M
|
$114.48 M
|
$97.32 M
|
$79.71 M
|
| Weighted Average Shares Out Diluted |
$200.19 M
|
$172.66 M
|
$169.79 M
|
$164.50 M
|
$150.04 M
|
$145.53 M
|
$126.90 M
|
$114.48 M
|
$99.55 M
|
$79.71 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
